A case for combined ovarian and breast cancer prevention.
Targeted prevention of ovarian cancer is hindered by the inaccessibility of ovarian tissue, lack of accepted biomarkers and low disease incidence. However, ovarian cancer has common risk factors and shared etiologies with breast cancer. Chemoprevention of ovarian cancer has been demonstrated incidentally during testing of novel breast cancer prevention drugs. Here it is hypothesized that the development of combined ovarian and breast cancer prevention strategies is a preferable strategy for ovarian cancer prevention.